Related Experiment Videos
Cilazapril in congestive heart failure. A pilot study.
W Kiowski1, H Drexler, T Meinertz
1Division of Cardiology, University Hospital, Basel, Switzerland.
Drugs
|January 1, 1991
Summary
Cilazapril significantly improved heart function and patient well-being in chronic heart failure patients. Continuous treatment maintained acute benefits, unlike placebo, leading to better New York Heart Association (NYHA) class.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Chronic heart failure (CHF) is a debilitating condition requiring effective management.
- Current treatments aim to improve hemodynamics and clinical outcomes.
Purpose of the Study:
- To evaluate the acute and long-term hemodynamic and clinical effects of cilazapril in patients with stable chronic heart failure.
- To compare cilazapril's efficacy against a placebo in patients already on digitalis and diuretics.
Main Methods:
- A single dose of cilazapril (2.5 or 5 mg) was administered to 33 CHF patients.
- A 3-month double-blind, placebo-controlled trial compared cilazapril (1.25-5 mg daily) with placebo in 24 patients.
- Hemodynamic parameters (e.g., mean arterial pressure, cardiac index) and New York Heart Association (NYHA) class were assessed.
Main Results:
- Acute cilazapril administration decreased mean arterial pressure and systemic vascular resistance while increasing cardiac index and stroke volume index.
- These acute hemodynamic improvements were sustained with 3 months of cilazapril treatment.
- 11 of 13 cilazapril recipients improved their NYHA class, compared to 2 of 11 placebo recipients.
Conclusions:
- Cilazapril demonstrates significant acute and sustained hemodynamic benefits in chronic heart failure.
- Long-term cilazapril treatment leads to functional improvement and enhanced patient well-being.
- Cilazapril is an effective therapeutic option for managing stable chronic heart failure.